by | Feb 27, 2023 | Uncategorized
The FDA announced several regulatory actions the past few weeks.Here is an overview of decisions that may be relevant to your practice.1. The agency granted fast track designation to AB-101 (Artiva Biotherapeutics), a nongenetically modified, cord blood-derived,...
by | Feb 23, 2023 | Uncategorized
Source: Cure Today articles Patients who used opioids long-term after undergoing an autologous stem cell transplant tended to have poorer survival outcomes, recent research showed. Read More
by | Feb 23, 2023 | Uncategorized
Researchers developed a highly accurate model that can predict which patients will achieve complete response to chimeric antigen receptor T-cell therapy for multiple myeloma.The model is based on clinical and metabolic data plus gut microbiome composition genomic...
by | Feb 21, 2023 | Uncategorized
A circulating tumor DNA liquid biopsy can predict the likelihood of early disease progression among patients treated with chimeric antigen receptor T-cell therapy for advanced multiple myeloma, study results showed.The noninvasive tool could be used to quantify a...
by | Feb 16, 2023 | Uncategorized
Source: Cure Today articles Carvykti and other drugs prove that there are still options for patients whose myeloma got worse on prior therapies. Read More
by | Feb 10, 2023 | Uncategorized
Idecabtagene vicleucel significantly extended PFS compared with standard regimens for adults with triple-class refractory multiple myeloma, results of the randomized phase 3 KarMMa-3 trial showed.A single-infusion of the modified cellular therapy also induced a...
